Welcome to our dedicated page for Matinas Biopharm news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharm stock.
Matinas BioPharma Holdings, Inc. (NYSE: MTNB) is a clinical-stage biopharmaceutical company dedicated to advancing innovative anti-infective therapies for orphan indications. Utilizing proprietary lipid-crystal nano-particle cochleate technology, Matinas BioPharma aims to enhance the safety, tolerability, and oral bioavailability of existing drugs, thereby reducing their toxicity and improving patient outcomes.
The company's leading drug candidate, MAT2203, is an orally-administered, encochleated formulation of amphotericin B, a broad-spectrum fungicidal agent. Currently in Phase 2 clinical trials, MAT2203 seeks to offer a less toxic and more effective oral treatment for severe fungal infections.
Another promising candidate is MAT2501, an orally-administered, encochleated formulation of amikacin. Amikacin is a broad-spectrum aminoglycoside antibiotic agent effective against acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram-negative bacterial infections. MAT2501 is currently in Phase 1 clinical trials, following an open Investigational New Drug (IND) application.
Matinas BioPharma's innovative approach positions the company at the forefront of developing next-generation anti-infective therapies. The firm's pipeline also includes other drug candidates that aim to address unmet medical needs in infectious disease treatment. By leveraging its nano-encapsulation technology, Matinas BioPharma is committed to creating safer and more effective treatments for patients.
Latest News:
- A photo accompanying this announcement is available
- Studies in neutropenic mouse model demonstrate prolonged and enhanced survival, reduced fungal burden, and improvement in lung infection.
- Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100
Matinas BioPharma (MTNB) reported 2022 financial results, posting $3.2 million in revenue, a substantial increase from $33,000 in 2021, attributed to its collaboration with BioNTech. Total costs rose to $27.8 million, reflecting advancements in clinical development. The company's net loss decreased to $21.0 million from $23.7 million year-over-year. Key milestones ahead include FDA meetings regarding MAT2203 for invasive fungal infections and potential non-dilutive funding from BARDA or NIH. Promising data from ongoing collaborations with BioNTech and National Resilience are expected in 2023, enhancing the application of their lipid nanocrystal platform.
Matinas BioPharma Holdings, Inc. (MTNB) will report its 2022 financial results on March 15, 2023, after market close. A conference call hosted by management will occur at 4:30 p.m. ET to discuss the results and provide a business update. The company focuses on innovative intracellular delivery of nucleic acids and small molecules via its lipid nanocrystal (LNC) platform, aimed at enhancing patient access and clinical impact. Matinas is developing its internal product portfolio and collaborating with pharmaceutical companies to leverage its LNC technology, which shows potential in overcoming current delivery challenges in therapies such as mRNA and vaccines.
Matinas BioPharma (NYSE American: MTNB) has announced that its oral formulation of amphotericin B, MAT2203, will be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) on April 18, 2023. The company is developing MAT2203 for treating invasive fungal infections with a focus on reducing toxicity associated with traditional intravenous amphotericin B. Presentations will cover a Phase II trial for cryptococcal meningitis and a case of osteomyelitis treatment. Matinas aims to leverage its lipid nanocrystal technology for broader applications, improving patient access and clinical outcomes.
Matinas BioPharma (MTNB) reported a successful 2022, validating its lipid nanocrystal (LNC) platform for delivering therapies, particularly MAT2203 for fungal infections. The company has partnerships with BioNTech and National Resilience, aiming for initial in vivo data by mid-2023. With approximately $28.8 million in cash, Matinas expects to fund operations through Q2 2024. The firm plans to engage with BARDA and the FDA regarding MAT2203's Phase 3 study. Key developments include a focus on nucleic acids and the potential for expanding internal product pipelines.
Matinas BioPharma (NYSE AMER: MTNB) will hold a conference call on January 30, 2023, at 4:30 p.m. ET to discuss its business outlook for 2023 and provide corporate updates. The call will cover details about ongoing programs and third-party collaborations. Interested participants can join via telephone or through a live webcast on the company's website, where the presentation will be archived for 90 days. Matinas focuses on enhancing intracellular delivery of nucleic acids and small molecules using its innovative lipid nanocrystal (LNC) technology, aiming to tackle challenges in drug delivery.
Matinas BioPharma (MTNB) announced a strategic collaboration with National Resilience, Inc., focusing on the oral delivery of nucleic acids using Matinas' lipid nanocrystal (LNC) platform. This agreement includes a comprehensive research program for designing, formulating, and testing nucleic acid formats. The LNC technology may enhance intracellular drug delivery, offering advantages over traditional methods with no observed immunogenicity or cytotoxicity. CEO Jerome D. Jabbour expressed excitement about the collaboration, emphasizing its distinct nature from ongoing projects with BioNTech.
Matinas BioPharma Holdings, Inc. (MTNB) announced significant progress in its Phase 2 EnACT study for MAT2203, achieving a remarkable 95% two-week survival rate in cryptococcal meningitis patients. The treatment surpassed primary endpoint thresholds, showing a 90% overall survival rate through 18 weeks. The pivotal Phase 3 trial is set to commence in Q1 2023, backed by the NIH. Financially, the company reported $33.1 million in cash, sufficient for operations through 2023, with a reduced net loss of $5.5 million for Q3 2022.
Matinas BioPharma Holdings (MTNB) announced a conference call on November 2, 2022, at 4:30 PM ET to discuss third-quarter financial results for the period ending September 31, 2022. The company specializes in intracellular delivery technologies for nucleic acids and small molecules via its lipid nanocrystal (LNC) platform. Their innovative approach aims to enhance drug delivery efficiency, positioning Matinas for future collaborations and product developments.
Matinas BioPharma Holdings announced positive interim results for MAT2203, an oral formulation of amphotericin B, from its Phase 2 EnACT trial for cryptococcal meningitis treatment. Notably, the two-week survival rate in Cohort 4 reached 95% among 40 patients, exceeding the primary endpoint for CSF yeast clearance. MAT2203 demonstrated favorable safety, showing no kidney toxicity over six weeks of treatment. A pivotal Phase 3 trial is set to begin in Q1 2023, aimed at further validating MAT2203's efficacy.
Matinas BioPharma (MTNB), a clinical-stage biopharmaceutical company, announced that CEO Jerome D. Jabbour will present at the ThinkEquity Investment Conference on October 26, 2022, at 10:30 a.m. ET. This event will take place at the Mandarin Oriental Hotel in New York City, where investor meetings are also scheduled. The company focuses on enhancing the intracellular delivery of nucleic acids and small molecules using its lipid nanocrystal (LNC) platform technology, aimed at addressing challenges in the drug delivery process.
FAQ
What is the current stock price of Matinas Biopharm (MTNB)?
What is the market cap of Matinas Biopharm (MTNB)?
What is Matinas BioPharma Holdings, Inc.?
What is MAT2203?
What is MAT2501?
What technology does Matinas BioPharma use?
What are the benefits of MAT2203?
What types of infections does MAT2501 target?
What is unique about Matinas BioPharma's approach?
Who can I contact for investor relations inquiries?
What is the status of MAT2203 clinical trials?
What recent achievements has Matinas BioPharma reported?
